Source: International Congress 2016 – Acute pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Elif Yilmazel Uçar (Erzurum, Turkey), Elif Yilmazel Uçar, Omer Araz, Bugra Kerget, Nafiye Yilmaz, Metin Akgün, Leyla Saglam. Comparison of long –term outcomes of 50 mg rt-PA and 100 mg rt-PA in the management of acute pulmonary embolism. Eur Respir J 2016; 48: Suppl. 60, 2461

Member's Comments

No comment yet.

Related content which might interest you: The treatment of sub massive pulmonary embolism: Thrombolytic or heparin? Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012 Hemorrhagic complications of treatment in patients with pulmonary embolism Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Fibrinolysis with tenecteplase in the management of massive pulmonary embolism Source: Eur Respir J 2004; 24: Suppl. 48, 559s Year: 2004 Comparision of catheter-directed therapy with the systemic thrombolysis for the treatment of acute pulmonary embolism with right ventricular dysfunction Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021 Treatment of acute pulmonary embolism Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Treatment of acute pulmonary embolism Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Treatment of acute pulmonary embolism Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 Treatment of acute pulmonary embolism Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Safety of long-term sildenafil 20 or 80 mg TID in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Efficacy of thrombolytic agents in the treatment of pulmonary embolism Source: Eur Respir J 2005; 26: 864-874 Year: 2005 Pulmonary embolism: who should receive thrombolysis? Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism Year: 2014 Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Comparison of two regimens of oral anticoagulation in pulmonary embolism Source: Eur Respir J 2006; 28: Suppl. 50, 632s Year: 2006 Septic pulmonary embolism in intravenous drug users. Source: International Congress 2017 – Pulmonary embolism Year: 2017 Comparison of local and systemic thrombolytic treatment for acute massive pulmonary embolism Source: Eur Respir J 2007; 30: Suppl. 51, 544s Year: 2007 Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Acute management of pulmonary embolism  Source: International Congress 2017 – Pulmonary emergencies year in review Year: 2017 The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019 Interventional treatment of pulmonary embolism: catheter-delivered local thrombolysis versus reduced-dose systemic thrombolysis Source: Virtual Congress 2021 – Pulmonary embolism: controversies in management Year: 2021